← Back to Blog

Menopause Hormone Therapy: What ACOG’s New Guideline Means for You

For more than 20 years, hormone therapy for menopause has carried a reputation it didn’t fully earn. After the Women’s Health Initiative (WHI) trials came out in the early 2000s, prescriptions dropped sharply, and many women who could have benefited went without treatment.

In October 2026 the American College of Obstetricians and Gynecologists (ACOG) published a new guideline, Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms. It replaces ACOG’s 2014 guidance and is its most complete menopause guidance to date (Contemporary OB/GYN). It gives a clear, evidence-based update on who benefits from menopausal hormone therapy (MHT), when to start it, how to think about the risks, and what to do if hormones aren’t right for you.

Here’s what changed and what it means for you.

The headline: hormone therapy is strongly recommended for hot flashes

ACOG now strongly recommends systemic hormone therapy to treat hot flashes and night sweats (vasomotor symptoms) in people with no medical reason to avoid hormones. The same strong recommendation covers sleep problems caused by hot flashes and night sweats.

• If you have a uterus: estrogen is combined with a progestogen (progesterone or a progestin) to protect the lining of the uterus.
• If you’ve had a hysterectomy: estrogen alone is usually enough.
• An alternative: conjugated estrogens combined with bazedoxifene can replace estrogen plus a progestogen. ACOG makes this a conditional recommendation, based on more limited evidence. It may suit women who want to avoid progestogen side effects like bleeding or breast tenderness.

The benefit is large. In studies the guideline cites, estrogen cut the number of hot flashes by more than half and their severity by about 70% compared with placebo.

This matches the Veterans Affairs and Department of Defense’s first menopause guideline, released in September 2026. It also strongly recommends systemic estradiol plus progesterone for hot flashes in women with a uterus (Epocrates).

Timing matters: before 60 or within 10 years

The most important practical point is when to start. ACOG strongly recommends starting hormone therapy before age 60 or within 10 years of when natural menopause began.

Starting early gives the best balance of benefits and risks. A Cochrane review of 19 trials and more than 40,000 women showed the difference clearly:

Starting after 60 isn’t automatically ruled out. ACOG says that choice should be made one person at a time, weighing how bad your symptoms are against your own risk of clots, stroke and heart disease.

Rethinking the WHI

Much of the fear around hormone therapy comes from the WHI. The new guideline puts those results in context:

• The WHI women were mostly older. About two-thirds were 60 or older. That makes the results hard to apply to healthy women in their late 40s and 50s, who are most likely to use hormone therapy and benefit from it.
• The absolute risks were small. With estrogen plus progestin over about 5.6 years, there were roughly 5 extra strokes, 10 extra blood clots and 5 extra invasive breast cancers per 1,000 women. With estrogen alone over about 7.2 years, there was no increase in invasive breast cancer.
• The WHI tested only one regimen: oral conjugated equine estrogen, with or without medroxyprogesterone acetate. Observational data suggest transdermal estradiol (patch, gel or spray), with or without micronized progesterone, may carry a lower clot risk.

The FDA has changed the labels too. On November 10, 2025, the FDA announced it would remove most of the boxed warning on hormone therapy products. That includes the warnings for heart disease, breast cancer and probable dementia. It also dropped the old “lowest dose for the shortest time” rule, and added guidance that starting before 60 or within 10 years of menopause gives the best balance of benefits and risks (Obstetrics & Gynecology). One boxed warning stays: estrogen taken alone raises the risk of uterine cancer in women who still have a uterus (Axios). That’s why those women also take a progestogen.

Can’t take hormones, or don’t want to?

You still have good options. ACOG graded several nonhormonal treatments, and two classes of medicine earned the same strong recommendation as hormone therapy.

One thing ACOG did not support: soy isoflavones and other plant estrogens, and herbal “menopause” supplements. The guideline says the evidence doesn’t show they work or are safe, and they aren’t tested for purity.

Who should not use hormone therapy

Hormone therapy isn’t right for everyone. ACOG lists these reasons to avoid it:

• Unexplained vaginal bleeding
• Current or past breast cancer
• Certain uterine and ovarian cancers (high-grade or advanced endometrial cancer, uterine sarcoma and some ovarian tumor types)
• Coronary heart disease
• Current or past blood clots (deep vein thrombosis or pulmonary embolism)
• Current or past stroke or heart attack
• Known clotting disorders
• Liver disease
• Pregnancy

In some cases, women with a history of early-stage endometrial cancer or high-grade serous ovarian cancer may still consider hormone therapy after talking it through with a gynecologic oncologist.

A personal decision, not a one-size-fits-all rule

ACOG stresses shared decision-making. Before you start, your clinician should talk with you about:

• How much your symptoms affect your life
• Your age and medical history
• Your heart disease risk, often estimated with a calculator such as the American College of Cardiology’s
• Your breast cancer risk, using tools such as the National Cancer Institute’s Breast Cancer Risk Assessment Tool or the Tyrer–Cuzick model
• Your personal and family history of blood clots. If clot risk is a concern, transdermal estrogen may be the better choice.

How long to stay on it is also personal. ACOG sets no automatic stopping point. It recommends regular check-ins about your risks and benefits over time.

What about mood?

Many women notice mood changes around menopause. ACOG found not enough evidence to recommend for or against hormone therapy for depression linked to menopause. If you meet the criteria for major depression, or depression is your main symptom, it should be treated like any other depression. SSRIs and SNRIs can help with both mood and hot flashes.

A few practical points

• Bleeding needs a check. Ongoing or unexpected bleeding after starting hormone therapy should be evaluated to rule out precancerous changes or cancer of the uterine lining.
• Choose FDA-approved products. Several FDA-approved “bioidentical” hormones are available. Custom-compounded bioidentical hormones aren’t FDA-tested, and there’s no reliable evidence for their safety or effectiveness.
• Hormone therapy treats symptoms, not disease. It isn’t recommended to prevent heart disease or other chronic conditions in women without symptoms.
• Not every night sweat is menopause. Night sweats that start years after menopause, or come with weight loss or fever, deserve a closer look.

The bottom line

If hot flashes, night sweats or the sleep problems they cause are hurting your quality of life, hormone therapy is a safe and effective option for many women, especially those under 60 or within 10 years of menopause. If hormones aren’t right for you, newer nonhormonal medicines work well too. The best next step is an honest conversation with your clinician about your symptoms, your health history and your goals.

This article is for general education and is not medical advice. Talk with your healthcare provider about whether any treatment is right for you.

Sources

• ACOG Clinical Practice Guideline No. 13: Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms, Obstetrics & Gynecology, published online October 15, 2026
• ACOG guideline expands menopause VMS, sleep, and mood recommendations, Contemporary OB/GYN
• Elimination of the Black Box Warning on Menopausal Hormone Therapy, Obstetrics & Gynecology, 2026
• FDA scraps “black box” warning from menopause hormone therapy, Axios
• What VA/DoD’s first menopause guideline means for prescribing, Epocrates